The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men’s Health-Reference-Cited by-同舟云学术

The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men’s Health

Published:2018-06-16 Issue:8 Volume:19 Page:
ISSN:1527-2737
Container-title:Current Urology Reports
language:en
Short-container-title:Curr Urol Rep

Author:

Said Mohammed A.,Mehta Akanksha

Publisher

Springer Science and Business Media LLC

Subject

Urology,General Medicine

Link

http://link.springer.com/article/10.1007/s11934-018-0814-z/fulltext.html

Reference48 articles.

1. • Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136–41 e5. This meta-analysis compared finasteride to other treatment options. The mean difference in hair count for men using 1 mg finasteride daily was 18.37 hairs/cm 2 compared to placebo. This difference was superior to low-level laser light therapy (17.66 hairs/cm 2 ) and 2% minoxidil twice daily (8.11 hairs/cm 2 ).

2. Sultan C, Lumbroso S, Poujol N, Boudon C, Georget V, Terouanne B, et al. Genetics and endocrinology of male sex differentiation: application to molecular study of male pseudohermaphroditism. C R Seances Soc Biol Fil. 1995;189(5):713–40.

3. • Gupta AK, Carviel J, MacLeod MA, Shear N. Assessing finasteride-associated sexual dysfunction using the FAERS database. J Eur Acad Dermatol Venereol. 2017;31(6):1069–75. The US Food and Drug Administration Adverse Event Reporting System (FAERS) database was assessed for finasteride-associated sexual dysfunction. There was a significant disproportionality in reporting of sexual dysfunction with the use of finasteride was observed whether finasteride was indicated for hair loss (ROR = 138.17, 95% CI 133.13, 143.4) or BPH (ROR = 93.88, 95% CI 84.62, 104.16). When these results were stratified by age, disproportionality was strongest at 31–45 years.

4. •• Kiguradze T, Temps WH, Yarnold PR, Cashy J, Brannigan RE, Nardone B, et al. Persistent erectile dysfunction in men exposed to the 5alpha-reductase inhibitors, finasteride, or dutasteride. PeerJ. 2017;5:e3020. A retrospective study by Kiguradze et al. found that in a cohort of men exposed to 5α-RIs, the duration of 5a-RI exposure was a more accurate predictor of persistent ED than many known risk factors. Specifically, among men < 43 years old exposed to finasteride 1 mg/day, 34 of 4,284 (0.8%) developed persistent ED, with ED persisting for an average of 4 years. For each 108 young men exposed for > 205 days to 1 mg finasteride, one additional young man experienced PED when compared to those men with shorter exposure.

5. Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011;8(6):1747–53.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study on the Efficacy and Potential Mechanism of Topical Shen Bai Hair Growing Decoction against Androgenetic Alopecia Based on Ultrahigh Performance Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry and RNA-seq;ACS Omega;2024-02-26

2. Impact of Microbial Infection on Sperm Parameters of Seminal Bacteria in Asymptomatic Subfertile Males;Urogenital Tract Infection;2023-12-31

3. Dietary marine-derived ingredients for stimulating hair cell cycle;Biomedicine & Pharmacotherapy;2023-07

4. Schizochytrium sp. Extracted Lipids Prevent Alopecia by Enhancing Antioxidation and Inhibiting Ferroptosis of Dermal Papilla Cells;Antioxidants;2023-06-23

5. Cell Therapy for Androgenetic Alopecia: Elixir or Trick?;Stem Cell Reviews and Reports;2023-06-05